Healthy adults
Conditions
Interventions
Daily ingestion 30 g of jelly containing konjac-origin glucosylceramide for 24 weeks.
Daily ingestion 30 g of placebo jelly for 24 weeks.
Sponsors
Hokkaido Information University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1.Subjects who fully understand significance, content and purpose of this study and who agree to participate in this study with a written informed consent. 2.Subjects who are aware of their cognitive decline such as forgetfulness. 3.Subjects who can carry out cognitive function test, write diary and questionnaire.
Exclusion criteria
Exclusion criteria: 1.Subjects whose MMSE score is <= 23 points. 2.Subjects with unusually high and/or low plasma amyloid be-ta. 3.Subjects who are under medication for dementia, Alzheimer's disease, psychiatric disorder and cerebrovascular disease. 4.Subjects with a history of (or suspected) psychiatric disorder and cerebrovascular disease. 5. Subjects with serious cerebrovascular, cardiac, hepatic, renal, gastrointestinal diseases, and/or affected with infectious diseases requiring reports to the authorities. 6. Subjects with major surgical history relevant to the digestive system such as gastrectomy, gastrorrhaphy, enterectomy, etc. 7. Subjects with unusually high and/or low blood pressure and/or abnormal physical data and hematological data. 8. Subjects with severe anemia. 9. Pre- or post-menopausal women complaining of obvious physical changes. 10. Subjects with dysphagia. 11. Subjects who are at risk of having allergic reactions to drugs or foods especially based on gelatin, mango, urushi, pistachio, cashew nut, latex rubber and birch. 12. Subjects who regularly take medicine, functional foods, and/or supplements which would affect cognitive function. 13. Heavy smokers, alcohol addicts or subjects with disordered lifestyle. 14. Subjects who donated either 400 ml whole blood within 16 weeks (women), 12 weeks (men), 200 ml whole blood within 4 weeks (men and women), or blood components within 2 weeks (men and women), prior to the current study. 15. Subjects who currently participate in other clinical trials, or participated within the last 4 weeks prior to the current study. 16. Any other medical and/or health reasons unfavorable to participation in the current study, as judged by the principal investigator.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| MMSE and plasma amyloid be-ta composite biomarker at 24 weeks after beginning the ingestion of test food. | — |
Countries
Japan
Contacts
Public ContactJun NISHIHIRA
Hokkaido Information University Health Information Science Center
Outcome results
None listed